Dysplastic changes should be absent. Multilineage dysplastic changes and >10% immature cells in the PB are prominent in aCML. CSF3R mutation should be demonstrated. This evidence concerns the gene CSF3R and atypical chronic myeloid leukemia, BCR-ABL1 negative.